Support Program for Breast Cancer
Trial Summary
What is the purpose of this trial?
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Do I have to stop taking my current medications for the trial?
The trial does not specify whether you need to stop taking your current medications. However, it focuses on ensuring you take your prescribed endocrine therapy medication as directed.
What data supports the effectiveness of the treatment Additional Support Program Via Text Messaging and Telephone-Based Counseling for breast cancer patients?
Research shows that text messaging programs can effectively support people with chronic diseases by improving health self-management and self-efficacy. Additionally, mobile health interventions, including text messaging, have been shown to help breast cancer patients manage their health better.12345
Is the Support Program for Breast Cancer safe for humans?
The safety of the Support Program for Breast Cancer, which includes text messaging and telephone-based counseling, is supported by studies showing that similar interventions help manage side effects and improve adherence to cancer treatments without causing harm. These programs have been used safely in cancer patients to provide guidance and monitor symptoms.46789
How does the Support Program for Breast Cancer differ from other treatments for breast cancer?
The Support Program for Breast Cancer is unique because it uses a mobile application to provide personalized information and a support network for women undergoing chemotherapy, aiming to improve their self-efficacy, social support, and symptom management, which can enhance their quality of life and psychological well-being.210111213
Research Team
Katherine E. Reeder-Hayes, MD
Principal Investigator
University of North Carolina, Chapel Hill
Eligibility Criteria
This trial is for breast cancer patients who've had surgery or other treatments, except reconstruction. They must have hormone receptor positive, HER2-neu negative cancer and started endocrine therapy within the last 6 months or plan to start within 6 weeks after joining. Participants need a smartphone for study activities.Inclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive online educational information about ET and are randomized to receive text message reminders, motivational interviewing counseling, or both for up to 9 months
Follow-up
Participants are monitored for ET adherence and overall health for up to 24 months post-randomization
Treatment Details
Interventions
- Additional Support Program Via Text Messaging and Telephone-Based Counseling (Hormone Therapy)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Alliance for Clinical Trials in Oncology
Lead Sponsor
Suzanne George
Alliance for Clinical Trials in Oncology
Chief Medical Officer since 2015
MD from Harvard Medical School
Evanthia Galanis
Alliance for Clinical Trials in Oncology
Chief Executive Officer since 2022
MD from Mayo Clinic
National Cancer Institute (NCI)
Collaborator
Dr. Douglas R. Lowy
National Cancer Institute (NCI)
Chief Executive Officer since 2023
MD from New York University School of Medicine
Dr. Monica Bertagnolli
National Cancer Institute (NCI)
Chief Medical Officer since 2022
MD from Harvard Medical School